Device Trial Radar · NCT03762408
Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.
Last checked: Nov 20, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Dec 15, 2017
Primary completion
May 29, 2020
Study completion May 29, 2020
Sponsor
- Lead sponsor
- OPKO Health, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Osteoarthritis Foundation International (OAFI)
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical trial with medical device, multicenter, single-blind (blind third party evaluation), randomized, comparative and in two paralell groups, to demonstrate the treatment according to usual clinical practice, of the combination of 50 mg Sodium Hyaluronate and 50 mg Chondroitin Sulfate (ENKO 1) in a single administration, has non-inferiority efficacy vs the comparator (Durolane; 60 mg HA crosslinked) in patients with symptomatic knee osteoarthritis after three months of follow-up.
Conditions
- Osteoarthritis, Knee
Interventions
ENKO 1Device
50 mg of HA/ 50 mg of CS in 5 ml
DurolaneDevice
60 mg HA crosslinked in 3 ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain ReliefTime frame: Change from baseline pain relief at 6 months.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Instituto Médico Arriaza
A Coruña, Spain
17 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.